Amendments to the Claims:

1-30. (Cancelled)

31. (Currently amended) A method of ~~altering~~ improving the pharmacokinetics of a drug metabolized by a mammalian cytochrome p450 enzyme selected from the group consisting of CYP1A1, CYP1A2, CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A2 and CYP3A4 enzymes in a mammalian subject, the method comprising:

co-administering to the subject with [[a]] the drug ~~metabolized by a drug-metabolizing mammalian cytochrome p450 enzyme~~ an effective amount of a morpholino antisense oligomer having a backbone composed of phosphorodiamidate linkages, wherein the antisense oligomer blocks expression of the mammalian cytochrome p450 enzyme, by hybridizing to a target RNA molecule which encodes the enzyme.

32. (Previously presented) The method of claim 31 in which the oligomer has a length of at least 15 nucleotides.

33. (Previously presented) The method of claim 31 in which the morpholino antisense oligomer hybridizes to a region of the target RNA molecule that includes the AUG translation start site.

34. (Previously presented) The method of claim 31 in which the target RNA is a pre-mRNA and the morpholino antisense oligomer hybridizes to a region of the pre-mRNA that includes an intron-exon boundary or an exon-intron boundary.

35. (Previously presented) The method of claim 31 in which the drug induces expression of the mammalian drug-metabolizing cytochrome p450 enzyme.

36. (Currently amended) The method of claim 34 ~~31~~ in which the morpholino antisense oligomer hybridizes to a region of the pre-mRNA that includes an exon-intron boundary ~~the mammalian cytochrome p450 is selected from the group consisting of CYP1A1, CYP1A2,~~

~~CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4~~.

37. (Previously presented) The method of claim 31 in which the mammalian cytochrome p450 is selected from the group consisting of CYP1A2, CYP2B1, CYP2E1, and CYP3A4.

38. (Previously presented) The method of claim 31 in which the mammalian cytochrome p450 is CYP3A4.

39. (Previously presented) The method of claim 31 in which the mammalian drug-metabolizing cytochrome p450 is a human drug-metabolizing cytochrome p450 enzyme.

40. (Currently amended) A method of inhibiting expression of a drug-metabolizing mammalian cytochrome p450 enzyme selected from the group consisting of CYP1A1, CYP1A2, CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A2 and CYP3A4 enzymes in a subject, the method comprising:

administering to the subject an effective amount of a morpholino antisense oligomer having a backbone composed of phosphorodiamidate linkages, wherein the antisense oligomer hybridizes to a target RNA molecule encoding a drug-metabolizing mammalian cytochrome p450 enzyme and inhibits expression of the enzyme.

41. (Previously presented) The method of claim 40 in which the antisense oligomer has a subunit length of at least 15 nucleotides.

42. (Previously presented) The method of claim 40 in which the morpholino antisense oligomer hybridizes to a region of the target RNA molecule that includes the AUG translation start site.

43. (Previously presented) The method of claim 40 in which the target RNA is a pre-mRNA and the morpholino antisense oligomer hybridizes to a region of the pre-mRNA that includes an intron-exon boundary or an exon-intron boundary.

44. (Currently amended) The method of claim 43 ~~40~~ in which the morpholino antisense oligomer hybridizes to a region of the pre-mRNA that includes an exon-intron boundary ~~mammalian cytochrome p450 is selected from the group consisting of CYP1A1, CYP1A2, CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4~~.

45. (Previously presented) The method of claim 40 in which the mammalian cytochrome p450 is selected from the group consisting of CYP1A2, CYP2B1, CYP2E1, and CYP3A4.

46. (Previously presented) The method of claim 40 in which the mammalian cytochrome p450 is CYP3A4.

47. (Previously presented) The method of claim 40 in which the mammalian cytochrome p450 is a drug-metabolizing human cytochrome p450 enzyme.